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LETTERS TO THE EDITORLoss of PRDM16 Is Unlikely
to Cause Cardiomyopathy
in 1p36 Deletion SyndromeTo the Editor: In the July 2013 issue of the American
Journal of Human Genetics, Arndt et al. stated that
PRDM16 (MIM 605557) haploinsufficiency is the cause
of cardiomyopathy of 1p36 deletion syndrome (MIM
607872).1 Their conclusion was partly based on ‘‘data
from array comparative genomic hybridization (CGH)’’
from 18 deletion syndrome cases, one of which was
their own and 17 of which were from publicly available
databases. Five of these cases were from the European
Cytogeneticists Association Register of Unbalanced
Chromosome Aberrations (ECARUCA). In their Figure 1,
all of the deletions are aligned to indicate common
PRDM16 involvement. We were puzzled to find that
three of the five ECARUCA cases listed only had
G-banded karyotypes, and in these cases, the authors
used the estimated position of the band (e.g.,
1p36.32 ¼ 2,300,000–5,400,000 in the UCSC Genome
Browser) as deletion positions. Of the ECARUCA cases
with array data (IDs 4593 and 4608), the breakpoints
were incorrectly listed and thus incorrectly presented
in Figure 1 (see our Table 1 for details). In neither of
these cases did PRDM16 lie within the deleted region.
This was correctly mentioned in the discussion for case
16 only. The deletion in case 15 was said to include
PRDM16, but not SKI, whereas the opposite is true.
Some of the three other ECARUCA cases might also
have deletions that do not contain PRDM16 given that
accurate characterization of a deletion by G-banding
and fluorescence in situ hybridization is difficult and
especially so on distal 1p. Moreover, the authors did
not mention the total number of cases listed as havingTable 1. Sited Cases and Actual Information from ECARUCA
Arndt et al.
Case ID
ECARUCA
Case ID
Annotated Aberration
in Arndt et al. Table S1a ECARU
10 2759 arr 1p36(0–12,700,000)31 46,XX
15 4608 arr 1p36(2,300,000–5,400,000)31 46,XX
.arr 1p
16 4593 arr 1p36(5,400,000–12,700,000)31 .arr 1p
17 4176 arr 1p36(0–5,400,000)31 46,XX
18 2758 arr 1p36(0–12,700,000)31 46,XX
Cases 10 and 15–18 in Arndt et al.1 were from ECARUCA, and the information give
(column 2) and information (column 4) can be seen for comparison, and correct
aAll coordinates are according to the UCSC Genome Browser (hg19).
bGenomic coordinates of PRDM16 are chr1: 2,985,742–3,355,185 (hg19).
cGenomic coordinates of SKI are chr1: 2,160,134–2,241,652 (hg19).
The Amera deletion in the 1p36.33p36.32 region in either
DECIPHER (n ¼ 39) or ECARUCA (n ¼ 39); only a few
(10%) of these cases had cardiomyopathy as a listed
phenotypic feature. Even though clinical information
might be incomplete, this contrasts the 23%–27% risk
of cardiomyopathy in 1p36 deletion syndrome. Another
relevant point not discussed by the authors is that ~40
large PRDM16 deletions, many including the terminal
exons of PRDM16, are listed in the Database of Genomic
Variants (DGV) and are all found in control individuals.
The presence of a high number of differently positioned
DGV deletions argues against pathogenicity of monoal-
lelic loss of PRDM16.
The authors also discussed eight cases with nonsyn-
dromic cardiomyopathy and seven different PRDM16
single-nucleotide variants, of which five were missense
variants and two were disruptive mutations. The latter
two mutations were both in exon 9 and both were de
novo, a strong suggestion of pathogenicity but maybe
not due to haploinsufficiency. Concerning the six cases
with five missense variants, family information was lack-
ing (n ¼ 5) or inconclusive (n ¼ 1), making it difficult
to draw conclusions about pathogenicity. None of these
missense variants were modeled in zebrafish. The authors
did not mention that two of these five variants, PRDM16
c.811G>A (p.Glu271Lys) and c.3301G>A (p.Val1101Met)
(RefSeq accession number NM_022114.3), are rare
SNPs found in Europeans and have dbSNP numbers
rs200052869 and rs201654872, respectively. The
p.Glu271Lys variant has a PolyPhen-2 score in the benign
range (HumVar score 0.005 and HumDiv score 0.059, un-
like what they list in their Table 1). The p.Val1101Met
variant also has a benign PolyPhen-2 HumVar score
(0.084) and was found in two affected individuals, indi-
cating that this is a founder variant of benign nature.
Haplotyping was not done for checking possible identity
by descent.CA Information Correction(s)
,del(1)(p36.32)dn no array data, de novo2
.ish del(1)(p36.32)(Vysis 1ptel-)dn
36.33p36.32(1–2,957,600)31
wrong position, PRDM16 not
deleted,b SKI within deletionc
36.32p36.22(3,999,632–11,988,296)31 wrong position
.ish del(1)(p36.3)(CP5401-)dn no array data
,del(1)(p36.22)dn no array data, de novoa
n in the article can be seen in column 3. The actual ECARUCA four-digit case ID
ions are listed in column 5.
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In our opinion, available (cyto)genetic data do not sup-
port the conclusion of the authors, i.e., that PRDM16
haploinsufficiency causes cardiomyopathy in 1p36 dele-
tion syndrome. Furthermore, only 2/7 PRDM16 variants
claimed to be mutations were proven to be most likely
pathogenic (the two de novo truncating mutations).
Even though zebrafish and mouse data suggest a role
for PRDM16 in cardiac development (impaired prolifera-
tive capacity and contractile dysfunction with uncou-
pling of cardiomyocytes in zebrafish and ventricular
hypoplasia in mice), we are not convinced that this is
the cardiomyopathy-associated gene in 1p36 deletion
syndrome.Nicole de Leeuw1 and Gunnar Houge2,*
1Department of Human Genetics, Radboud University
Medical Centre, 6500 Nijmegen, the Netherlands;
2Center for Medical Genetics and Molecular Medicine,
Haukeland University Hospital, 5021 Bergen, Norway
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The URLs for data presented herein are as follows:
Database of Genomic Variants (DGV), http://dgv.tcag.ca/dgv/app/
home
dbSNP, http://www.ncbi.nlm.nih.gov/
ECARUCA, http://www.ecaruca.net
Online Mendelian Inheritance in Man (OMIM), http://www.
omim.org
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Society of Human Genetics. All rights reserved.Reponse to de Leeuw and HougeTo the Editor: We thank Drs. de Leeuw and Houge for
their interest in our work, and we are grateful for the
opportunity to respond to their thoughtful comments.
However, we are concerned that they might have misread
some of the fundamental conclusions outlined in our
paper.1
We completely agree that haploinsufficiency of
PRDM16 (MIM 605557) is an unlikely or uncommon
cause of the cardiomyopathy in 1p36 deletion syndrome
(MIM 607872). In the context of substantial genomic
deletions, there are numerous potential mechanisms,
including contiguous or multigene effects, long-range reg-
ulatory effects, undetected rearrangements, and position
effects, to name but a few. It was for this very reason
that we used the initial inferences from existing data on
1p36 deletions simply as a means of generating a list of
candidate genes for the cardiomyopathy seen in this
syndrome. Indeed, we not only tested multiple genes
within the 1p36 deletion in our zebrafish model but
also chose to finally build a transgenic line expressing a
dominant-negative truncation mutant. For example, we
tested for mutations in SKI (MIM 164780) in non-
syndromic cardiomyopathy and even demonstrated the
interaction between PRDM16 and SKI in zebrafish with
the result that we did not exclude the effect of SKI, as
noted in the manuscript.
Most importantly, in our original paper, we went on to
obtain three additional independent lines of evidencebefore drawing any conclusions regarding the role of
PRDM16 in cardiomyopathy: (1) PRDM16 mutations in
nonsyndromic forms of left ventricular noncompaction
(MIM 604169), (2) a highly significant excess of deleterious
PRDM16 variants in adult dilated cardiomyopathy (DCM
[MIM 115200]), and (3) in vivo modeling data of several
PRDM16 variants in zebrafish. Together, all these data un-
equivocally support our assertion that mutations in
PRDM16 are a cause of human myocardial disease.
Although it remains conceivable, as we suggested, that
PRDM16 haploinsufficiency does contribute to the cardiac
or other phenotypes in some of the complex deletions
involving 1p36, we do not think that this is the most com-
mon mechanism for the reasons outlined in detail in our
original paper.
On the specific details that Drs. de Leeuw and Houge
outline in their letter, there are several important consider-
ations., 21. The genomic boundaries that we used for fine map-
ping of PRDM16 in 1p36 deletion syndrome were
based on the information that was publically avail-
able when the manuscript was submitted. Subse-
quent additions to the database have clarified the
genomic boundaries of two deletions. We apologize
that the genomic positions based on karyotype infor-
mation from the ECARUCA (European Cytogeneti-
cists Association Register of Unbalanced Chromo-
some Aberrations) cases were indicated as array
data in our submitted manuscript. The lack of an
obvious cardiomyopathy phenotype in other014
